

Michele Aieta

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2149224/michele-aieta-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

2,235
citations

26
h-index

44
g-index

107
ext. papers

2,639
ext. citations

4.2
avg, IF

4.33
L-index

#	Paper	IF	Citations
99	Therapeutic management of a symptomatic Kaposi's sarcoma patient with renal failure undergoing haemodialysis: A case report.. <i>Dermatology Reports</i> , 2022 , 14, 9113	0.9	0
98	Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective Trial. <i>Oncologist</i> , 2021 , 26, 740-750	5.7	3
97	A fully automated assay to detect the expression of pan-cytokeratins and of EML4-ALK fusion protein in circulating tumour cells (CTCs) predicts outcome of non-small cell lung cancer (NSCLC) patients. <i>Translational Lung Cancer Research</i> , 2021 , 10, 80-92	4.4	3
96	Association between neutropenia and response to ramucirumab and paclitaxel in patients with metastatic gastric cancer. <i>Anti-Cancer Drugs</i> , 2020 , 31, 632-636	2.4	2
95	Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study. <i>Advances in Therapy</i> , 2020 , 37, 1145-1155	4.1	52
94	Association between neutropenia and survival to nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer. <i>Scientific Reports</i> , 2020 , 10, 19281	4.9	4
93	Focus on lung cancer screening. <i>Journal of Thoracic Disease</i> , 2020 , 12, 3815-3820	2.6	8
92	Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results. <i>Journal of Translational Medicine</i> , 2019 , 17, 296	8.5	7
91	The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. <i>Investigational New Drugs</i> , 2019 , 37, 524-530	4.3	2
90	Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?. <i>Medicine (United States)</i> , 2019 , 98, e16249	1.8	
89	Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis. <i>Future Oncology</i> , 2019 , 15, 2423-2433	3.6	48
88	A multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): CHEIRON study.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5050-5050	2.2	
87	Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas. <i>International Journal of Molecular Sciences</i> , 2019 , 21,	6.3	3
86	Poor outcome for patients with gastric cancer and lung metastases treated with ramucirumab and paclitaxel. <i>Anti-Cancer Drugs</i> , 2019 , 30, e0789	2.4	2
85	Influence of Age and the Gleason Score in the Choice of Novel Hormonal Therapies Before and After Chemotherapy. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019 , 34, 141-146	3.9	2
84	Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223. <i>OncoTargets and Therapy</i> , 2019 , 12, 9-13	4.4	6
83	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 474-485	21.7	39

82	Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma. <i>Medical Oncology</i> , 2018 , 35, 28	3.7	9
81	Lenvatinib for the treatment of renal cell carcinoma. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 507-512	5.9	6
80	Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer. <i>Investigational New Drugs</i> , 2018 , 36, 1133-1137	4.3	14
79	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). <i>BMC Cancer</i> , 2018 , 18, 552	4.8	9
78	Lower urinary tract infections from external beam radiation therapy in prostate cancer: A single institution experience. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018 , 23, 298-299	1.5	
77	Association between ramucirumab-related hypertension and response to treatment in patients with metastatic gastric cancer. <i>Oncotarget</i> , 2018 , 9, 22332-22339	3.3	11
76	Randomized, multicentre phase II trial of the sequencing of radium-223 and docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS396-TPS396	2.2	
75	Corticosteroid switch in heavily pre-treated castration-resistant prostate cancer patients progressed on abiraterone acetate plus prednisone. <i>Investigational New Drugs</i> , 2018 , 36, 1110-1115	4.3	7
74	Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study <i>Annals of Oncology</i> , 2018 , 29, 2328-2333	10.3	77
73	Is there a role for immunotherapy in malignant pleural mesothelioma?. <i>Medical Oncology</i> , 2018 , 35, 98	3.7	4
72	Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study. <i>Medicine (United States)</i> , 2018 , 97, e10745	1.8	8
71	Possible applications of circulating tumor cells in patients with non small cell lung cancer. <i>Lung Cancer</i> , 2017 , 107, 59-64	5.9	13
70	Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone. <i>Prostate</i> , 2017 , 77, 1012-1019	4.2	4
69	Progress and challenges in the treatment of small cell lung cancer. <i>Medical Oncology</i> , 2017 , 34, 110	3.7	22
68	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study: primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017 , 82, 237-246	7.5	30
67	Liquid biopsy for monitoring anaplastic lymphoma kinase inhibitors in non-small cell lung cancer: two cases compared. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1391-S1396	2.6	6
66	Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2017 , 9, S1359-S1363	2.6	3
65	Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4568-4568	2.2	3

64	9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 501-501	2.2	23
63	TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma. <i>Oncotarget</i> , 2017 , 8, 21229-21240	3.3	13
62	Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer. <i>Future Oncology</i> , 2016 , 12, 493-502	3.6	6
61	Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. <i>Annals of Oncology</i> , 2016 , 27, 1055-1061	10.3	49
60	Systemic immune-inflammation index to predict the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 547-547	2.2	1
59	Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib. <i>Oncotarget</i> , 2016 , 7, 54564-54571	3.3	89
58	Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. <i>Frontiers in Pharmacology</i> , 2016 , 7, 376	5.6	93
57	Monitoring and Characterization of Circulating Tumor Cells (CTCs) in a Patient With EML4-ALK-Positive Non-Small Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2016 , 17, e173-e177	4.9	19
56	Somatostatin Analog Therapy in Small Cell Lung Cancer. <i>Seminars in Nuclear Medicine</i> , 2016 , 46, 239-42	5.4	6
55	Evaluation of Social Support, Quality of Life, and Body Image in Women with Breast Cancer. <i>Breast Care</i> , 2016 , 11, 28-32	2.4	32
54	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016 , 16, 1387-1401	5.4	16
53	Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and younger. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 265.e15-21	2.8	6
52	When crizotinib-induced bradycardia becomes symptomatic: role of concomitant drugs. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 761-3	3.5	5
51	Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management. <i>Future Oncology</i> , 2015 , 11, 2043-8	3.6	26
50	Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study. <i>European Urology</i> , 2015 , 68, 147-53	10.2	62
49	Impact of new agents (NAs) on post-docetaxel (DOC) survival of octogenarians with metastatic castration resistant prostate cancer (mCRPC) patients (pts): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2015 , 33, e16017-e16017	2.2	1
48	Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. <i>World Journal of Gastroenterology</i> , 2015 , 21, 7281-8	5.6	8
47	Phase II study of everolimus in combination with octreotide LAR in first line setting for patients with neuroendocrine tumors (I.T.M.O. study): A 4-year update.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15199-e15199	2.2	

46	Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. <i>Cancer</i> , 2014 , 120, 2457-63	6.4	52
45	Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?. <i>Medical Oncology</i> , 2014 , 31, 78	3.7	4
44	Neuroendocrine differentiation in prostate cancer: current and emerging therapy strategies. <i>Critical Reviews in Oncology/Hematology</i> , 2014 , 92, 11-24	7	60
43	Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey. <i>PLoS ONE</i> , 2014 , 9, e105268	3.7	25
42	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014 , 10, 1353-60	3.6	21
41	Pyrosequencing evaluation of low-frequency KRAS mutant alleles for EGF receptor therapy selection in metastatic colorectal carcinoma. <i>Future Oncology</i> , 2014 , 10, 713-23	3.6	6
40	Long-term survival in small cell lung cancer: a case report and review of the literature. <i>Future Oncology</i> , 2014 , 10, 523-8	3.6	11
39	New cancer drugs: the Italian unsatisfactory solution. <i>Annals of Oncology</i> , 2014 , 25, 1448	10.3	1
38	Selected case from the Arkadi M. Rywlin International Pathology Slide Series: Leiomyomatosis peritonealis disseminata: report of 3 cases with extensive review of the literature. <i>Advances in Anatomic Pathology</i> , 2014 , 21, 201-15	5.1	15
37	Poor survival in prostate cancer patients with primary refractoriness to docetaxel. <i>European Urology</i> , 2014 , 65, 505-7	10.2	17
36	Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 501-6	4.7	7
35	Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. <i>Lancet Oncology</i> , 2014 , 15, 713-21	21.7	131
34	Lymphopenia and clinical outcome of elderly patients treated with sunitinib for metastatic renal cell cancer. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 156-63	3.6	21
33	Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, 182-9	3.3	18
32	Clinical outcomes of patients (pts) age 80 or older treated with docetaxel (DOC) as first-line chemotherapy for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (DELPHI study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 92-92	2.2	2
31	Clinical outcomes of patients (pts) age 60 or younger treated with docetaxel (DOC) for castration-resistant prostate cancer (CRPC): Results of an Italian multicenter retrospective study (CYCLOP study).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 214-214	2.2	
30	Circulating tumor cells: utopia or reality?. <i>Future Oncology</i> , 2013 , 9, 1337-52	3.6	17
29	Metabolic syndrome as a peculiar target for management of prostate cancer patients. <i>Clinical Genitourinary Cancer</i> , 2013 , 11, 211-20	3.3	14

28	Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. <i>Lung Cancer</i> , 2013 , 81, 328-336	5.9	45
27	The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. <i>Critical Reviews in Oncology/Hematology</i> , 2013 , 86, 42-51	7	36
26	Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. <i>Future Oncology</i> , 2013 , 9, 127-33	3.6	1
25	Carcinogenesis of pancreatic adenocarcinoma: precursor lesions. <i>International Journal of Molecular Sciences</i> , 2013 , 14, 19731-62	6.3	39
24	Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry. <i>Bone Marrow Transplantation</i> , 2013 , 48, 414-8	4.4	14
23	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013 , 9, 889-97	3.6	27
22	Everolimus in combination with octreotide LAR as the first-line treatment for advanced neuroendocrine tumors: A phase II trial of the I.T.M.O. (Italian Trials in Medical Oncology) group.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 4136-4136	2.2	2
21	A pilot characterization of human lung NSCLC by protein pathway activation mapping. <i>Journal of Thoracic Oncology</i> , 2012 , 7, 1755-1766	8.9	19
20	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012 , 110, E661-6	5.6	47
19	Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. <i>British Journal of Cancer</i> , 2012 , 107, 1286-94	8.7	46
18	Evaluation of molecular prognostic and predictive factors: an important step towards personalised treatment in non small cell lung cancer. <i>Medical Oncology</i> , 2012 , 29, 1599-605	3.7	3
17	Identification of a new insertion in exon 20 of EGFR in a woman with NSCLC. <i>Medical Oncology</i> , 2012 , 29, 3198-201	3.7	4
16	Anal metastasis from breast cancer: a case report and review of the literature. <i>Future Oncology</i> , 2012 , 8, 333-6	3.6	10
15	Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience. <i>European Journal of Clinical Pharmacology</i> , 2012 , 68, 505-12	2.8	20
14	Reflections about off-label use of anticancer drugs. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 604	3.2	1
13	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011 , 107, 234-9	5.6	71
12	Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. <i>Journal of Proteome Research</i> , 2011 , 10, 3089-97	5.6	30
11	The clinical impact of a cardiologic follow-up in breast cancer survivors: an observational study. <i>International Journal of Immunopathology and Pharmacology</i> , 2010 , 23, 1221-7	3	6

10	M30 neoepitope expression in epithelial cancer: quantification of apoptosis in circulating tumor cells by CellSearch analysis. <i>Clinical Cancer Research</i> , 2010 , 16, 5233-43	12.9	110
9	Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. <i>European Urology</i> , 2010 , 58, 906-11	10.2	48
8	Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. <i>Annals of Oncology</i> , 2009 , 20, 1535-1542	10.3	155
7	Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4469-74	2.2	114
6	Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know. <i>Future Oncology</i> , 2009 , 5, 837-41	3.6	6
5	Phase II study of oxaliplatin and gemcitabine salvage chemotherapy in patients with cisplatin-refractory nonseminomatous germ cell tumor. <i>European Urology</i> , 2006 , 50, 1032-8; discussion 1038-9	10.2	51
4	Weekly gemcitabine, paclitaxel, oxaliplatin combination chemotherapy in patients with Cisplatin-refractory germ cell tumor: preliminary experience. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004 , 27, 457-60	2.7	17
3	Role and limits of salvage chemotherapy in breast cancer patients treated with high-dose chemotherapy. <i>Annals of Oncology</i> , 2003 , 14, 1794-5	10.3	
2	Salvage Treatment with Epirubicin and/or Paclitaxel in Metastatic Breast Cancer Patients Relapsed after High-dose Chemotherapy with Peripheral Blood Progenitor Cells. <i>Tumori</i> , 2001 , 87, 134-137	1.7	1
1	Relationship of serum lactate dehydrogenase level with first remission length in adult acute lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1987 , 66, 49-53	4.5	5